title: Pharmacological discrimination between muscarinic receptor signal transduction cascades with bethanechol chloride.
abstract: 1. Muscarinic agonist specificity is limited, making it difficult to match receptor subtypes with signal transduction cascades that mediate ion channel modulation. We have characterized the inhibitory effects of two muscarinic agonists, oxotremorine-M (Oxo-M) and bethanechol chloride (BeCh), on Ca(2+) currents in neonatal rat superior cervical ganglion neurons. 2. Oxo-M-mediated (10 micro M) inhibition occurred via two signaling pathways. The first pathway inhibited whole cell peak currents, consisting primarily of N-type current, but not FPL 64176-induced, long-lasting tail currents, comprised entirely of L-type current. Inhibited currents displayed slowed activation kinetics and voltage dependence, characteristics of membrane-delimited inhibition. Current inhibition was blocked by the selective M(2) receptor antagonist, methoctramine (METH; 100 nM), or following pertussis toxin (PTX) pretreatment. 3. Activation of the second pathway inhibited both peak and long-lasting tail currents. This pathway was voltage-independent, PTX-insensitive, but sensitive to internal Ca(2+) chelator concentration. Muscarinic toxin 7 (MT-7, 100 nM), an irreversible M(1) receptor antagonist, eliminated this inhibition. Oxo-M (100 micro M) decreased L- and N-type channel activities in cell-attached patches, indicating that a diffusible second messenger is involved. 4. BeCh (100 micro M) also inhibited whole cell currents via the membrane-delimited pathway. Blocking M(4) receptors with 100 nM pirenzepine (in the presence of MT-7) had no effect, while antagonizing M(2) receptors with METH abolished inhibition. Concentrations of BeCh as high as 3 mM failed to inhibit either peak or long-lasting tail currents following PTX pretreatment. 5. These results indicate that BeCh may be an effective tool for selectively activating M(2) receptor stimulation of the membrane-delimited pathway.
authors.affiliation: Program in Neuroscience, Program in Cellular & Molecular Physiology, Department of Physiology, University of Massachusetts Medical Center, 55 Lake Ave. North, Worcester, MA 01655, U.S.A.
authors.forename: Liwang
authors.initials: L
authors.lastname: Liu
authors.forename: Ann R
authors.initials: AR
authors.lastname: Rittenhouse
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D018723:Bethanechol / Q000494:pharmacology*; D020746:Calcium Channels, L-Type / Q000187:drug effects; D020864:Calcium Channels, N-Type / Q000187:drug effects; D020013:Calcium Signaling / Q000187:drug effects* / Q000502:physiology; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D018721:Muscarinic Agonists / Q000494:pharmacology*; D010095:Oxotremorine / Q000031:analogs & derivatives* / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D037342:Pertussis Toxin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043585:Receptor, Muscarinic M2 / Q000187:drug effects*; D043588:Receptor, Muscarinic M4 / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology*; D017783:Superior Cervical Ganglion / Q000187:drug effects
chemical_list: D020746:Calcium Channels, L-Type; D020864:Calcium Channels, N-Type; D018721:Muscarinic Agonists; D043585:Receptor, Muscarinic M2; D043588:Receptor, Muscarinic M4; D018723:Bethanechol; D004533:Egtazic Acid; D010095:Oxotremorine; C042743:oxotremorine M; D037342:Pertussis Toxin; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid